Indorama Ventures Past Earnings Performance
Past criteria checks 0/6
Indorama Ventures's earnings have been declining at an average annual rate of -25.9%, while the Chemicals industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 13% per year.
Key information
-25.9%
Earnings growth rate
-25.9%
EPS growth rate
Chemicals Industry Growth | 8.0% |
Revenue growth rate | 13.0% |
Return on equity | -21.6% |
Net Margin | -6.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indorama Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 551,767 | -33,758 | 60,079 | 0 |
30 Jun 24 | 553,119 | -34,847 | 60,382 | 0 |
31 Mar 24 | 543,824 | -11,438 | 59,290 | 0 |
31 Dec 23 | 544,296 | -11,548 | 58,737 | 0 |
30 Sep 23 | 561,228 | -10,599 | 57,711 | 0 |
30 Jun 23 | 600,913 | -2,657 | 59,823 | 0 |
31 Mar 23 | 650,887 | 17,210 | 63,067 | 0 |
31 Dec 22 | 660,378 | 30,256 | 62,936 | 0 |
30 Sep 22 | 648,360 | 47,126 | 61,648 | 0 |
30 Jun 22 | 596,117 | 45,537 | 57,016 | 0 |
31 Mar 22 | 519,408 | 33,595 | 50,422 | 0 |
31 Dec 21 | 470,555 | 25,538 | 47,137 | 0 |
30 Sep 21 | 421,682 | 21,603 | 44,235 | 0 |
30 Jun 21 | 375,854 | 15,435 | 41,881 | 0 |
31 Mar 21 | 339,531 | 7,102 | 38,887 | 0 |
31 Dec 20 | 333,602 | 1,665 | 38,378 | 0 |
30 Sep 20 | 327,950 | -1,310 | 36,613 | 0 |
30 Jun 20 | 331,111 | -973 | 35,160 | 0 |
31 Mar 20 | 350,929 | 1,213 | 35,821 | 0 |
31 Dec 19 | 354,672 | 4,275 | 34,181 | 0 |
30 Sep 19 | 368,047 | 8,072 | 33,430 | 0 |
30 Jun 19 | 379,665 | 17,334 | 32,587 | 0 |
31 Mar 19 | 368,174 | 23,309 | 30,566 | 0 |
31 Dec 18 | 348,255 | 25,415 | 28,318 | 0 |
30 Sep 18 | 327,382 | 33,064 | 27,175 | 0 |
30 Jun 18 | 303,907 | 26,526 | 27,597 | 0 |
31 Mar 18 | 291,919 | 21,220 | 26,316 | 0 |
31 Dec 17 | 287,335 | 19,833 | 25,799 | 0 |
30 Sep 17 | 281,315 | 12,790 | 24,962 | 0 |
30 Jun 17 | 274,508 | 12,458 | 22,564 | 0 |
31 Mar 17 | 269,508 | 15,472 | 22,711 | 0 |
31 Dec 16 | 255,130 | 15,147 | 21,772 | 0 |
30 Sep 16 | 247,350 | 12,332 | 21,450 | 0 |
30 Jun 16 | 243,995 | 9,680 | 20,927 | 0 |
31 Mar 16 | 238,839 | 9,199 | 19,841 | 0 |
31 Dec 15 | 235,284 | 5,559 | 19,168 | 0 |
30 Sep 15 | 232,822 | 4,772 | 18,243 | 0 |
30 Jun 15 | 233,826 | 5,092 | 17,555 | 0 |
31 Mar 15 | 236,147 | 1,367 | 16,865 | 0 |
31 Dec 14 | 243,907 | 1,532 | 16,590 | 0 |
30 Sep 14 | 247,126 | 1,969 | 16,171 | 0 |
30 Jun 14 | 242,844 | 2,472 | 15,050 | 0 |
31 Mar 14 | 236,008 | 1,203 | 13,757 | 0 |
31 Dec 13 | 229,923 | 1,326 | 12,848 | 0 |
Quality Earnings: IVL-R is currently unprofitable.
Growing Profit Margin: IVL-R is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVL-R is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.
Accelerating Growth: Unable to compare IVL-R's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVL-R is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (28.8%).
Return on Equity
High ROE: IVL-R has a negative Return on Equity (-21.65%), as it is currently unprofitable.